Exelixis Patent Company LLC

Exelixis, Inc.

Lg Chem, Ltd

Bristol-myers Squibb Compnay

Byung Gyu Kim

Yong Wang

Timothy Patrick Forsyth

James William Leahy

Jeff Z Chen

Grace Mann

Tai Phat Huynh

Brian Hugh Ridgway

Sergey Epshteyn

Gary Lee Lewis

Xian Shi

Matthew Sangyup Lee

Morrison B Mac

Craig Stacy Takeuchi

Joan C Sangalang

Charles K Marlowe

William Bajjalieh

Suleyman Bahceci

Elena S Koltun

Wei Xu

T G Murali Dhar

Chang Seok Lee

Lynne Canne Bannen

Naing N Aay

Patrick C Kearney

S David Brown

Young Kwan Kim

Adam Galan

Sunghoon Ma

Sang Dae Lee

Mohamed Ibrahim

Seung Yup Paek

Peiwen Zhou

Arlyn Arcalas

Hongwang Du

Michael Pack

Joon Won Jeong

Eun Sil Choi

Robin Tammie Noguchi

Wai Ki Vicky Chan

Brian Kane

Hyun Woo Joo

Sang Yun Park

Henry William Beecroft Johnson

Lisa E Meyr

John Woolfrey

Sung Wook Kim

Seung Wan Kang

Compounds having the chemical formula 1, a method for producing the compounds of chemical formula 1, a pharmaceutical composition comprising same, and use thereof as a GPR120 agonist for prevention or treatment of inflammation or metabolic diseases such as diabetes, complications from diabetes, obesity, non-alcoholic fatty liver disease, fatty liver disease, and osteoporosis.

Biaryl derivative as GPR120 agonist

Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R, R, R, R, R, R, R, x, y, L, G, Z, the bond denoted by 'q', the ring system denoted by 'A' and the ring system denoted by &#x201c;B&#x201d; are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders. 

ROR&#x3b3; modulators

The present invention is directed to a compound of Formula I or a single isomer thereof; where the compound is optionally as a pharmaceutically acceptable salt, hydrate, solvate or combination thereof, in addition to methods of preparing a Compound of Formula I, and methods of using a Compound of Formula I to treat cancer.

Inhibitors of the hedgehog pathway

This invention relates to certain pyrimidine derivative inhibitors of JAK-2, having Formula (I): wherein D, E, L, Z, R, R, R, and n1 are as defined in the specification, pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and methods of use thereof.

4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as JAK-2 modulators and methods of use

Inhibitors of hedgehog pathway

Growing community of inventors

San Mateo, CA, United States of America

Byung Gyu Kim